- Home
- CTRN vs TVRD Comparison
CTRN vs TVRD Comparison
Compare CTRN & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRN
- TVRD
- Stock Information
- Founded
- CTRN 1946
- TVRD 2017
- Country
- CTRN United States
- TVRD United States
- Employees
- CTRN N/A
- TVRD N/A
- Industry
- CTRN Clothing/Shoe/Accessory Stores
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- CTRN Consumer Discretionary
- TVRD Health Care
- Exchange
- CTRN Nasdaq
- TVRD Nasdaq
- Market Cap
- CTRN 270.0M
- TVRD 246.5M
- IPO Year
- CTRN 2005
- TVRD N/A
- Fundamental
- Price
- CTRN $31.16
- TVRD $40.68
- Analyst Decision
- CTRN Buy
- TVRD Strong Buy
- Analyst Count
- CTRN 2
- TVRD 5
- Target Price
- CTRN $31.50
- TVRD $59.20
- AVG Volume (30 Days)
- CTRN 88.5K
- TVRD 67.6K
- Earning Date
- CTRN 08-26-2025
- TVRD 11-21-2025
- Dividend Yield
- CTRN N/A
- TVRD N/A
- EPS Growth
- CTRN N/A
- TVRD N/A
- EPS
- CTRN N/A
- TVRD N/A
- Revenue
- CTRN $782,716,000.00
- TVRD N/A
- Revenue This Year
- CTRN $7.81
- TVRD N/A
- Revenue Next Year
- CTRN $4.94
- TVRD N/A
- P/E Ratio
- CTRN N/A
- TVRD N/A
- Revenue Growth
- CTRN 3.32
- TVRD N/A
- 52 Week Low
- CTRN $16.18
- TVRD $8.13
- 52 Week High
- CTRN $39.37
- TVRD $42.10
- Technical
- Relative Strength Index (RSI)
- CTRN 43.99
- TVRD 70.68
- Support Level
- CTRN $29.60
- TVRD $36.05
- Resistance Level
- CTRN $33.09
- TVRD $42.10
- Average True Range (ATR)
- CTRN 1.49
- TVRD 2.87
- MACD
- CTRN -0.13
- TVRD 0.07
- Stochastic Oscillator
- CTRN 32.50
- TVRD 82.26
About CTRN Citi Trends Inc.
Citi Trends Inc is a retailer of urban fashion apparel and accessories in the United States. The company offers apparel, including fashion sportswear for men and women, as well as children, such as newborns, infants, toddlers, boys, and girls; accessories comprising handbags, jewelry, footwear, belts, intimate apparel, scrubs, and sleepwear; and functional and decorative home products, as well as beauty products, books and toys.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.